Latest Expert Opinions

Signal
Opinion
Expert
TOP PICK
TOP PICK
August 28, 2018

This is a specialty pharma company. They have been focused on dermatology products, the lead being Absorbica. He’s excited by their development pipeline. They bought the Canadian assets of Cardiome and have successfully integrated them. This came with tax losses along with the pipelines. Together, they help make Cipher incredibly cheap at its current price. There was an issue with inventory of their US partner, but that has now been resolved. He expects the recovery to show good earnings momentum for the back half of this year, then the release of new products. The company has dropped from $18--it was caught up in the run-up of prescription prices (Valeant) and then the run-down. While their prices were high, they tried to get into the US in a big way, and that failed. That cost them about $10 million and hurt their share price, but that failure is long past. He likes it a lot at its current price. (Analysts’ price target is $6.06)

This is a specialty pharma company. They have been focused on dermatology products, the lead being Absorbica. He’s excited by their development pipeline. They bought the Canadian assets of Cardiome and have successfully integrated them. This came with tax losses along with the pipelines. Together, they help make Cipher incredibly cheap at its current price. There was an issue with inventory of their US partner, but that has now been resolved. He expects the recovery to show good earnings momentum for the back half of this year, then the release of new products. The company has dropped from $18--it was caught up in the run-up of prescription prices (Valeant) and then the run-down. While their prices were high, they tried to get into the US in a big way, and that failed. That cost them about $10 million and hurt their share price, but that failure is long past. He likes it a lot at its current price. (Analysts’ price target is $6.06)

James Hodgins
Chief Investment Officer, Curvature Hedge Strategies
Price
$3.530
Owned
Yes
TOP PICK
TOP PICK
August 28, 2018

This is a pure play in phosphate. It does mining and processing. He sees it as a special situation, likely to be taken over. Their original investment was a plant in Brazil, backed by Cargills. Then they purchased Conda Phosphate from Agrium as part of Agrium’s merger divestitures. This makes sense for Itafos because it has other projects nearby. If there is an ag cycle, this will be the go-to small cap name. (Analysts’ price target is $4.00)

Itafos (IFOS-X)
August 28, 2018

This is a pure play in phosphate. It does mining and processing. He sees it as a special situation, likely to be taken over. Their original investment was a plant in Brazil, backed by Cargills. Then they purchased Conda Phosphate from Agrium as part of Agrium’s merger divestitures. This makes sense for Itafos because it has other projects nearby. If there is an ag cycle, this will be the go-to small cap name. (Analysts’ price target is $4.00)

James Hodgins
Chief Investment Officer, Curvature Hedge Strategies
Price
$2.190
Owned
Yes